Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL568436 | 0.82 | HTR2C (0.49) | HTR2CADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL23617909 | 0.80 | HTR2C (0.43) | HTR2CADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL569181 | 0.80 | TP53 (0.46) | HTR2CADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL30978693 | 0.80 | TP53 (0.46) | HTR2CADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL5740049 | 0.79 | HSD17B10 (0.50) | HTR2CADORA3ARHSD11B1AKR1C3 | |
| SCHEMBL6588001 | 0.78 | MAOB (0.47) | HTR2CHSD11B1HTR2ACYP19A1MAOB | |
| SCHEMBL11869980 | 0.75 | AR (0.46) | ADORA3ARHSD11B1AKR1C3S100A4 | |
| SCHEMBL19302757 | 0.75 | AR (0.46) | ADORA3ARHSD11B1AKR1C3S100A4 | |
| SCHEMBL30737888 | 0.75 | AR (0.46) | ADORA3ARHSD11B1AKR1C3S100A4 | |
| SCHEMBL2929675 | 0.75 | AR (0.46) | ADORA3ARHSD11B1AKR1C3S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042480-B1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2013-05-01 | — | — | EP | disclosed |
| CN-101489984-B | Aminoindan derivative or salt thereof | ASTELLAS PHARMA INC | 2013-04-03 | — | — | CN | disclosed |
| US-8013018-B2 | Aminoindane derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| CN-101489984-A | Aminoindan derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2042480-A1 | AMINOINDAN DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186916-A1 | AMINOINDANE DERIVATIVE OR SALT THEREOF | GRIN3A, OPRL1, GRIN2A | HTR2C 169/4885ADORA3 67/4885AR 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.